Our Clinical Trials
1479-0008
Lung CancerBeamion LUNG-2: A Phase III, open-label, randomized, activecontrolled, multi-centre trial evaluating orally administered BI 1810631 compared with standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic nonsquamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations
Lines of Therapy: 1st Line Metastatic and Locally Advanced20200041
Lung CancerA Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)
Lines of Therapy: Other20210031
MelanomaA Randomized, Double-blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared with Opdivo (Nivolumab) in Subjects with Treatment-naïve Unrespectable or Metastatic Melanoma
Lines of Therapy: 1st Line Metastatic and Locally Advanced61186372NS2012 COPERNICUS
Lung CancerA Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Lines of Therapy: 1st Line Metastatic and Locally Advanced, 2nd Line Metastatic61186372NSC2007
Lung CancerA Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivantamab + lazertinib
Lines of Therapy: 1st Line Metastatic and Locally AdvancedBGB-3111-308
LymphomaA Phase 3, Open-Label Study of Zanubrutinib Plus Anti-CD20 Versus Rituximab and Lenalidomide (R2) in Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Lines of Therapy: OtherJ3M-MC-JZQB SUNRAY-01
Lung CancerA Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression
Lines of Therapy: 1st Line Metastatic and Locally AdvancedPUMA-ALI-1201
Breast CancerA PHASE 2 STUDY OF ALISERTIB IN COMBINATION WITH ENDOCRINE THERAPY IN PATIENTS WITH HR+, HER2-NEGATIVE RECURRENT OR METASTATIC BREAST CANCER
Lines of Therapy: 3rd Line + MetastaticTP-CA-002
Lung CancerTEMPUS GEMINI NSCLC SURVEILLANCE STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Non-Small Cell Lung Cancer (NSCLC)
Lines of Therapy: Neo-Adjuvant, 1st Line Metastatic and Locally Advanced